Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Antibody-drug conjugate (ADC)Antibody-drug conjugate (ADC)Antibody-drug conjugate (ADC)

Firefly Biologics General Information

Preclinical studies in solid and liquid tumors showed significant tumor volume reduction with single administration at low doses

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Firefly Biologics's pipeline data

Book a demo

Key Partnerships

Eli Lilly

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Firefly Biologics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Firefly Biologics's complete valuation and funding history, request access »

Firefly Biologics Investors

Versant Ventures
Investor Type: Venture Capital
Holding: Minority
MPM BioImpact
Investor Type: Venture Capital
Holding: Minority
Decheng Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »